March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Intraocular Pressure In Eyes Treated With Intravitreal Combination Of 1mg Triamcinolone Acetonide And 1.25mg Bevacizumab
Author Affiliations & Notes
  • Valerie C. Lerebours
    Ophthalmology, Howard University Hospital, Washington, Dist. of Columbia
  • Jane S. Myung, MD
    Ophthalmology, Retina Associates of New York, New York, New York
  • Jesse N. Cohen
    Ophthalmology, Retina Associates of New York, New York, New York
  • Ben Z. Cohen, MD
    Ophthalmology, Retina Associates of New York, New York, New York
  • Footnotes
    Commercial Relationships  Valerie C. Lerebours, None; Jane S. Myung, MD, None; Jesse N. Cohen, None; Ben Z. Cohen, MD, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 881. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Valerie C. Lerebours, Jane S. Myung, MD, Jesse N. Cohen, Ben Z. Cohen, MD; Intraocular Pressure In Eyes Treated With Intravitreal Combination Of 1mg Triamcinolone Acetonide And 1.25mg Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2012;53(14):881.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To measure the intraocular pressure in eyes treated with intravitreal combination of 1mg of triamcinolone acetonide and 1.25mg of bevacizumab (TAB).

Methods: : A retrospective chart review of 86 patients (135 eyes) with various retinal pathologies treated with intravitreal TAB from August 2009 to June 2011 by a single physician were reviewed. Indications for treatment included age related macular degeneration, clinically significant diabetic macular edema and venous occlusive disease. Baseline intraocular pressure was recorded prior to the first injection of TAB. The intraocular pressures at three separate office visits over a six month period after the initial injection were also obtained. All intraocular pressures were measured by the administering physician using a calibrated Goldmann applanation tonometer.

Results: : The mean baseline intraocular pressure prior to the initial intravitreal injection was 14.70 mmHg. The mean intraocular pressure prior to additional injections on three subsequent visits over a six month period was 14.81 ± 0.24 mmHg. The mean intraocular pressure immediately post injection on the same three visits was 15.49 ± 0.25 mmHg. Two eyes (2.33%) developed an intraocular pressure greater than 21mmHg during the post injection period. Twenty-seven eyes (31.40%) were on intraocular pressure lowering medications prior to receiving the combined therapeutic drug injection due to preexisting glaucoma. In this group, there was a mean increase of 0.69 mmHg between pre and post injection intraocular pressures with a mean number of 1.55 injections given to each eye over the 6 month period (P=0.006).

Conclusions: : This study suggests that combination intravitreal 1mg triamcinolone acetonide and 1.25mg bevacizumab does not result in a significant increase in intraocular pressure. However, subgroup analysis of eyes with preexisting glaucoma showed a significant increase in intraocular pressure and may be a relative contraindication to use of this combination therapy.

Keywords: intraocular pressure • injection • corticosteroids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×